Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Chris Lascola"'
Autor:
Sheheryar Kabraji, Jing Ni, Sarah Sammons, Tianyu Li, Amanda E.D. Van Swearingen, Yanzhi Wang, Alyssa Pereslete, Liangge Hsu, Pamela J. DiPiro, Chris Lascola, Heather Moore, Melissa Hughes, Akshara S. Raghavendra, Maria Gule-Monroe, Rashmi K. Murthy, Eric P. Winer, Carey K. Anders, Jean J. Zhao, Nancy U. Lin
Publikováno v:
Clin Cancer Res
Purpose: Brain metastases can occur in up to 50% of patients with metastatic HER2-positive breast cancer. Because patients with active brain metastases were excluded from previous pivotal clinical trials, the central nervous system (CNS) activity of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd732bc462df40bf3795d7807bf20c2f
https://doi.org/10.1158/1078-0432.ccr-22-1138
https://doi.org/10.1158/1078-0432.ccr-22-1138
Autor:
Nancy U. Lin, Jean J. Zhao, Carey K. Anders, Eric P. Winer, Rashmi K. Murthy, Maria Gule-Monroe, Akshara S. Raghavendra, Melissa Hughes, Heather Moore, Chris Lascola, Pamela J. DiPiro, Liangge Hsu, Alyssa Pereslete, Yanzhi Wang, Amanda E.D. Van Swearingen, Tianyu Li, Sarah Sammons, Jing Ni, Sheheryar Kabraji
Purpose:Brain metastases can occur in up to 50% of patients with metastatic HER2-positive breast cancer. Because patients with active brain metastases were excluded from previous pivotal clinical trials, the central nervous system (CNS) activity of t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::071e468ffb7bb336ccd6cd64f6d1d7b1
https://doi.org/10.1158/1078-0432.c.6532872.v1
https://doi.org/10.1158/1078-0432.c.6532872.v1
Autor:
Nancy U. Lin, Jean J. Zhao, Carey K. Anders, Eric P. Winer, Rashmi K. Murthy, Maria Gule-Monroe, Akshara S. Raghavendra, Melissa Hughes, Heather Moore, Chris Lascola, Pamela J. DiPiro, Liangge Hsu, Alyssa Pereslete, Yanzhi Wang, Amanda E.D. Van Swearingen, Tianyu Li, Sarah Sammons, Jing Ni, Sheheryar Kabraji
Figures S1 and S2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79cd1c4aae60dc5fd89e823c842f4a0a
https://doi.org/10.1158/1078-0432.22489053.v1
https://doi.org/10.1158/1078-0432.22489053.v1
Autor:
Sheheryar Kabraji, Jing Ni, Sarah Sammons, Amanda ED Van Swearingen, Yanzhi Wang, Alyssa M Pereslete, Liangge Hsu, Chris Lascola, Heather Moore, Melissa Hughes, Akshara S Raghavendra, Maria Gule-Monroe, Rashmi K Murthy, Eric P Winer, Carey K Anders, Jean J Zhao, Nancy U Lin
Publikováno v:
Cancer Research. 82:PD4-05
Purpose: Up to half of patients (pts) with HER2+ metastatic breast cancer (MBC) will develop BCBM. Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate (ADC) with demonstrated efficacy in previously treated pts with HER2+ MBC. However, few pt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::229e007abb9005a5fbb80dce140e9780
https://doi.org/10.1158/1538-7445.sabcs21-pd4-05
https://doi.org/10.1158/1538-7445.sabcs21-pd4-05
Autor:
Vladimira Mouravieva, Chris Lascola, Masaki Kimura, Matvey Tsivian, Vladimir Mouraviev, Ines Batinic-Haberle, Thomas J. Polascik, Talaignair N. Venkatraman, Haiyan Wang
Publikováno v:
Journal of Endourology. :111222131612007
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fe3ef41cf6f19df72ec92cb4be7d95e4
https://doi.org/10.1089/end.2011.0133
https://doi.org/10.1089/end.2011.0133